Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio(R) Therapeutics
November 17, 2022
November 17, 2022
WILMINGTON, Delaware, Nov. 17 -- AstraZeneca, a biopharmaceutical company, issued the following news release on Nov. 16, 2022:
Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio(R) Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
The acquisition creates an opportunity to accelerate Alexion's growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expe . . .
Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio(R) Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
The acquisition creates an opportunity to accelerate Alexion's growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expe . . .